Rubric Capital Management (New York)’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Rubric Capital Management (New York)’s Portfolio MACK Stock Details MACK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-704,564	Closed	-$2.96M	–	71
2018 Q3	$2.96M	Buy	704,564 +99,360	+16%	+$419K	0.31%	42
2018 Q2	$2.34M	Hold	605,204	–	–	0.23%	39
2018 Q1	$3.83M	Buy	605,204 +83,784	+16%	+$693K	0.36%	48
2017 Q4	$4.21M	Buy	521,420 +91,990	+21%	+$858K	0.52%	42
2017 Q3	$4.91M	Buy	+429,430	New	+$4.51M	0.44%	44

Other funds holding MACK

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sepio Capital Salt Lake City, Utah $1.99B AUM 22.34% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

WIM

Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Rubric Capital Management (New York)'s MACK Position: Q4 2018 in Review

Rubric Capital Management (New York) sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 704,564 shares — an estimated $2.96M sold.

Rubric Capital Management (New York) first reported a position in MACK in Q3 2017 and held it in 5 quarters. The position peaked at $4.91M in Q3 2017. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

Rubric Capital Management (New York) reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Rubric Capital Management (New York) sold 704,564 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $2.96M.
Rubric Capital Management (New York) first reported a position in Merrimack Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
Rubric Capital Management (New York)'s Merrimack Pharmaceuticals, Inc. position peaked at $4.91M in Q3 2017.
56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on Rubric Capital Management (New York)'s 13F filing for Q4 2018, filed 13 Feb 2019.